Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism

Journal of Infectious Diseases

Volumn 191, Issue 11, 2005, Pages 1961-1970

  Calazans, Alexandre ^a   Brindeiro, Rodrigo ^a   Brindeiro, Patrícia ^a   Verli, Hugo ^b   Arruda, Mônica B ^a   Gonzalez, Luis Manuel Felipe ^a   Guimarães, Jorge A ^b   Diaz, Ricardo Sobhie ^c   Antunes, Octavio A C ^a   Tanuri, Amilcar ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; VIRUS RNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOST SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CONSENSUS SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; TIME FACTORS;

EID: 21044449399     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/430002     Document Type: Article

References (51)

1. Carpenter C, Fischi M, Hammer S, et al. Antiretroviral therapy for HIV infection. JAMA 1996; 276:146-54.
2. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection. JAMA 1998; 280:35-41.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-33.
4. Ruiz L, Nijhuis M, Boucher TC, et al. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1 infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:19-28.
5. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003; 17:1339-49.
6. Piliero PJ. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin Investig Drugs 2002; 11:1295-301.
7. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003; 32:18-29.
8. Condra HJ, Schleif AW, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71.
9. Hirsch MS, Brun-Vézinet F, Dáquila RT, et al. Antiretroviral resistance testing in adult HIV-1 infection: recommendations of an international AIDS Society-USA panel. JAMA 2000; 283:2417-26.
10. Iversen A, Shafer R, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70:1086-90.
11. Schmit JC, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996; 174:962-8.
12. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 1998; 42: 2775-83.
13. Condra HJ, Holder JD, Schleif AW, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:8270-6.
14. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760-6.
15. Patick AK, Duran M, Cao DY, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998; 42:2637-44.
16. Shafer RW, Hsu P, Patick AK, Craig C, Brendel V. Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J Virol 1999; 73:6197-202.
17. Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77:4836-47.
18. Muzammil S, Ross P, Freire E. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 2003; 42:631-8.
19. Rose RB, Craik CS, Stroud RM. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 1998; 37:2607-21.
20. Scott WRP, Schiffer CA. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 2000; 8:1259-65.
21. Kantor R, Fessel WJ, Zolopa AR, et al. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother 2002; 46:1086-92.
22. Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999; 13:2349-59.
23. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001; 29:296-9.
24. Kijak GH, Rubio AE, Pampuro SE, et al. Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med 2003; 4:72-8.
25. Schmidt B, Walter H, Moschik B, et al. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS 2000; 14:1731-8.
26. Schmidt B, Walter H, Zeitler N, Korn K. Genotypic drug resistance interpretation systems-the cutting edge of antiretroviral therapy. AIDS Rev 2002; 4:148-56.
27. Van Laethem K, De Luca A, Antinori A, Cingolani A, Bañadme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-infected patients. Antivir Ther 2002; 7:123-9.
28. Fleury H, Recordon-Pinson P, Caumont A, et al. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses 2003; 19:41-7.
29. Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003; 5:25-35.
30. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000; 14:1489-95.
31. Brindeiro RM, Diaz RS, Sabino EC, et al. Brazilian network for HIV drug resistance surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 2003; 17:1063-9.
32. Morgado MG, Sabino EC, Shpaer EG, et al. V3 region polymorphism in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/European prototype and detection of subtype F. AIDS Res Hum Retroviruses 1994; 10:569-76.
33. Tanuri A, Vicente ACP, Otsuki K, et al. Genetic variation and susceptibilities to protease inhibitors among subtypes B and F isolates in Brazil. Antimicrob Agents Chemother 1999; 43:253-8.
34. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 2001; 23:193-202.
35. Brindeiro PA, Brindeiro RM, Mortensen C, et al. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 2002; 40:4512-9.
36. Ives KJ, Jacobsen H, Galpin SA, et al. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J Antimicrob Chemother 1997; 39:771-9.
37. Kaldor SW, Kalish VJ, Davies JF 2nd, et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997; 40:3979-85.
38. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol 1986; 59:284-91.
39. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol 1995; 69:5431-6.
40. Hertogs K, De Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269-76.
41. Holland JJ, de la Torre JC, Clarke DK, Duarte E. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J Virol 1991; 65:2960-7.
42. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, Vanderpol S. Rapid evolution of RNA genomes. Science 1982; 215:1577-85.
43. Maree AF, Keulen W, Boucher CA, De Boer RJ. Estimating relative fitness in viral competition experiments. J Virol 2000; 74:11067-72.
44. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999; 73:3744-52.
45. Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-7.
46. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002; 186:617-25.
47. Abecasis A, Gomes P, Derdelinckx I, et al. L89I/V: a novel mutation selected by protease inhibitor therapy in subtype G, but not in subtype B-infected patients [abstract]. Antivir Ther 2003;8:S140.
48. Caride E, Brindeiro RM, Kallas EG, et al. Sexual transmission of HIV-1 isolate showing G→A hypermutation. J Clin Virol 2002; 23:179-89.
49. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424:94-8.
50. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424:99-103.
51. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 1997; 71:6662-70.